TABLE 2.
Mean Changes in Total Costs, Hospitalizations, Pseudomonas Infections, and Other Health Care Resource Utilization
| Variable | Pre | Post | P value |
|---|---|---|---|
| Total costs, $ | 216,381 (124,066) | 329,583 (86,843) | < 0.00001 |
| Facilities costs, $ | 21,995 (36,454) | 7,245.75 (17,984) | < 0.00001 |
| Professional costs, $ | 11,603 (12,931) | 6,129 (6,984) | < 0.00001 |
| Pharmacy costs, $ | 182,783 (117,629) | 316,635 (76,714) | < 0.00001 |
| Hospitalizations | 7.7 (7.2) | 3.9 (5.5) | < 0.00001 |
| Pseudomonas infections, n | 0.27 (1.002) | 0.1 (0.361) | 0.833 |
| Dornase alfa prescriptions, n | 4.2 (4.1) | 3.8 (4.2) | 0.276 |
| Dornase alfa cost, $ | 17,707 (18,929) | 15,721 (19,045) | 0.263 |
| Inhaled aztreonam prescriptions, n | 0.61 (1.47) | 0.41 (1.2) | 0.826 |
| Inhaled aztreonam costs, $ | 5,155 (12,657) | 3,756 (11,023) | 0.857 |
| Inhaled tobramycin prescriptions, n | 2.36 (1.69) | 2.29 (1.86) | 0.726 |
| Inhaled tobramycin costs, $ | 1,382 (3,503) | 1,572 (3,808) | 0.976 |
| Inhaled amikacin prescriptions, n | 0.51 (1.92) | 0.29 (1.35) | 0.857 |
| Inhaled amikacin costs, $ | 5,345 (20,092) | 3,382 (15,579) | 0.857 |
| Insulin prescriptions, n | 1 (3.16) | 0.84 (2.53) | 0.897 |
| Insulin costs, $ | 361 (1,239) | 306 (969) | 0.889 |
| Oral diabetes prescriptions, n | 0.43 (2.94) | 0.22 (1.27) | 0.873 |
| Oral diabetes costs, $ | 214 (1,450) | 106 (611) | 0.873 |
| PERT prescriptions, n | 5.5 (3.4) | 4.9 (3.4) | 0.153 |
| PERT costs, $ | 26,188 (21,446) | 26,173 (19,774) | 0.741 |
Table of results from 51 continuously enrolled members who started therapy with elexacaftor/tezacaftor/ivacaftor. Total study duration was 20 months. Pre- and post-periods were 10 months before and after elexacaftor/tezacaftor/ivacaftor use, respectively. All data are presented as mean change per patient. Total costs were broken down by specific site. Facilities costs include hospital-related services. Professional costs include all nonpharmacy and physician services. All P values were generated using Wilcoxon signed-rank tests. Data are shown as mean (SD).
PERT = pancreatic enzyme replacement therapy.